Literature DB >> 23303651

Efficacy and safety of a clinical protocol for expectant management of selected women diagnosed with a tubal ectopic pregnancy.

D Mavrelos1, H Nicks, A Jamil, W Hoo, E Jauniaux, D Jurkovic.   

Abstract

OBJECTIVE: To validate the efficacy and safety of our clinical protocol for expectant management of selected women diagnosed with tubal ectopic pregnancy.
METHODS: This was a prospective observational study carried out in the early pregnancy unit of a London inner-city university teaching hospital from 1(st) January 2008 to 31(st) May 2011. All women presenting with suspected early pregnancy complications were assessed clinically and by transvaginal ultrasound. Those with a conclusive ultrasound diagnosis of tubal ectopic pregnancy were selected for either surgical or expectant management. Selection criteria for expectant management were clinical stability with no or minimal abdominal pain, no evidence of significant hemoperitoneum on ultrasound scan, ectopic pregnancy measuring < 30 mm in mean diameter with no evidence of embryonic cardiac activity, serum β-human chorionic gonadotropin (β-hCG) < 1500 IU/L and the woman's consent. All women selected for expectant management were followed up as outpatients until the ectopic pregnancy regressed spontaneously (resolution of clinical symptoms, serum β-hCG < 20 IU/L/negative urine pregnancy test) or surgical intervention was required. We recorded the rate of interventions, complications and length of follow-up.
RESULTS: During the study period 339/11 520 (2.9% (95% CI, 2.59-3.21%)) women were diagnosed with tubal ectopic pregnancy. Six women opted to participate in an ongoing randomized controlled trial and were excluded from further analysis. One hundred and sixty-five (49.5% (95% CI, 44.2-55.0%)) of the 333 remaining women met the criteria for expectant management; 146/333 (43.8% (95% CI, 38.5-49.1%)) of them opted for expectant management and 104/333 (31.2% (95% CI, 26.2-36.2%)) of all tubal ectopics resolved without requiring any intervention. All women with failed expectant management were treated by laparoscopic salpingectomy/salpingotomy and none of them required a blood transfusion.
CONCLUSION: Our clinical protocol for expectant management of tubal ectopic pregnancies eliminates the need for medical or surgical treatment in more than a third of women diagnosed with tubal ectopic pregnancy with a minimum risk of adverse outcome.
Copyright © 2013 ISUOG. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23303651     DOI: 10.1002/uog.12401

Source DB:  PubMed          Journal:  Ultrasound Obstet Gynecol        ISSN: 0960-7692            Impact factor:   7.299


  10 in total

1.  Predictive values of the ratio of beta-human chorionic gonadotropin for failure of salpingostomy in ectopic pregnancy.

Authors:  Xiu Li; Chen Zhang; Yuhong Li; Jiangjing Yuan; Qi Lu; Yudong Wang
Journal:  Int J Clin Exp Pathol       Date:  2019-03-01

2.  The impact of expectant management, systemic methotrexate and surgery on subsequent pregnancy outcomes in tubal ectopic pregnancy.

Authors:  E Demirdag; I Guler; S Abay; Y Oguz; M Erdem; A Erdem
Journal:  Ir J Med Sci       Date:  2016-02-19       Impact factor: 1.568

Review 3.  Efficacy and safety of expectant management in the treatment of tubal ectopic pregnancy: a systematic review and meta-analysis.

Authors:  G E Colombo; M Leonardi; M Armour; H Di Somma; T Dinh; F da Silva Costa; L Wong; S Armour; G Condous
Journal:  Hum Reprod Open       Date:  2020-10-25

Review 4.  Ectopic pregnancy secondary to in vitro fertilisation-embryo transfer: pathogenic mechanisms and management strategies.

Authors:  Bassem Refaat; Elizabeth Dalton; William L Ledger
Journal:  Reprod Biol Endocrinol       Date:  2015-04-12       Impact factor: 5.211

5.  β-hCG resolution times during expectant management of tubal ectopic pregnancies.

Authors:  D Mavrelos; M Memtsa; S Helmy; G Derdelis; E Jauniaux; D Jurkovic
Journal:  BMC Womens Health       Date:  2015-05-21       Impact factor: 2.809

6.  Effect of an Active vs Expectant Management Strategy on Successful Resolution of Pregnancy Among Patients With a Persisting Pregnancy of Unknown Location: The ACT or NOT Randomized Clinical Trial.

Authors:  Kurt T Barnhart; Karl R Hansen; Mary D Stephenson; Rebecca Usadi; Anne Z Steiner; Marcelle I Cedars; Emily S Jungheim; Kathleen M Hoeger; Stephen A Krawetz; Benjie Mills; Meredith Alston; Christos Coutifaris; Suneeta Senapati; Sarita Sonalkar; Michael P Diamond; Robert A Wild; Mitchell Rosen; Mary D Sammel; Nanette Santoro; Esther Eisenberg; Hao Huang; Heping Zhang
Journal:  JAMA       Date:  2021-08-03       Impact factor: 56.272

7.  Phase II single arm open label multicentre clinical trial to evaluate the efficacy and side effects of a combination of gefitinib and methotrexate to treat tubal ectopic pregnancies (GEM II): study protocol.

Authors:  Andrew W Horne; Monika M Skubisz; Ann Doust; W Colin Duncan; Euan Wallace; Hilary O D Critchley; Terrance G Johns; Jane E Norman; Siladitya Bhattacharya; Jill Mollison; Michael Rassmusen; Stephen Tong
Journal:  BMJ Open       Date:  2013-07-19       Impact factor: 2.692

8.  Trophoblastic infiltration in tubal pregnancy evaluated by immunohistochemistry and correlation with variation of Beta-human chorionic gonadotropin.

Authors:  Danyelle Farias Ferreira; Julio Elito Júnior; Edward Araujo Júnior; João Norberto Stavale; Luiz Camano; Antonio Fernandes Moron
Journal:  Patholog Res Int       Date:  2014-01-09

9.  Expectant management for abdominal pregnancy.

Authors:  Koji Yasumoto; Yukiyasu Sato; Yusuke Ueda; Takuma Ito; Hiromi Kawaguchi; Masataka Nakajima; Akira Muneshige
Journal:  Gynecol Minim Invasive Ther       Date:  2016-12-13

10.  A multi-centre, double-blind, placebo-controlled, randomised trial of combination methotrexate and gefitinib versus methotrexate alone to treat tubal ectopic pregnancies (GEM3): trial protocol.

Authors:  James May; Colin Duncan; Ben Mol; Siladitya Bhattacharya; Jane Daniels; Lee Middleton; Catherine Hewitt; Arri Coomarasamy; Davor Jurkovic; Tom Bourne; Cecilia Bottomley; Alexandra Peace-Gadsby; Ann Doust; Stephen Tong; Andrew W Horne
Journal:  Trials       Date:  2018-11-20       Impact factor: 2.279

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.